Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-blinding, Randomized Controlled, Phase II Clinical Trial on Combined Chemotherapy of Endostar (Recombinant Human Endostatin) for Untreated Patients With Advanced Melanoma

NCT00813449 is registered in ClinicalTrials.gov with Simcere Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT00813449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00813449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-blinding, Randomized Controlled, Phase II Clinical Trial on Combined Chemotherapy of Endostar (Recombinant Human Endostatin) for Untreated Patients With Advanced Melanoma
Lead sponsor
Simcere Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2008
Completion date
August 31, 2010
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, untreated patients